A cytokine network involving IL-36γ, IL-23, and IL-22 promotes antimicrobial defense and recovery from intestinal barrier damage

Proceedings of the National Academy of Sciences of the United States of America

Volumn 115, Issue 22, 2018, Pages E5076-E5085

  Ngo, Vu L ^a   Abo, Hirohito ^a   Maxim, Estera ^a   Harusato, Akihito ^a   Geem, Duke ^a   Medina Contreras, Oscar ^a   Merlin, Didier ^a,b   Gewirtz, Andrew T ^a   Nusrat, Asma ^c   Denning, Timothy L ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

^b ATLANTA VA MEDICAL CENTER   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Inflammatory bowel disease; Innate immunity; Interleukin; Repair

Indexed keywords

CD103 ANTIGEN; CD11B ANTIGEN; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 36 RECEPTOR; INTERLEUKIN 36GAMMA; INTERLEUKIN RECEPTOR; MYELOID DIFFERENTIATION FACTOR 88; NOTCH2 RECEPTOR; POLYPEPTIDE ANTIBIOTIC AGENT; TRANSCRIPTION FACTOR REL; UNCLASSIFIED DRUG; INTERLEUKIN DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLON INJURY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; HOST RESISTANCE; IN VITRO STUDY; IN VIVO STUDY; INTESTINE EPITHELIUM; INTRACELLULAR SIGNALING; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; GENETICS; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASE; INNATE IMMUNITY; INTESTINE MUCOSA; METABOLISM; TRANSGENIC MOUSE; WOUND HEALING;

ANIMALS; IMMUNITY, INNATE; INFLAMMATORY BOWEL DISEASES; INTERLEUKINS; INTESTINAL MUCOSA; MICE; MICE, TRANSGENIC; WOUND HEALING;

EID: 85047919596     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1718902115     Document Type: Article

References (64)

1. Martini E, Krug SM, Siegmund B, Neurath MF, Becker C (2017) Mend your fences: The epithelial barrier and its relationship with mucosal immunity in inflammatory bowel disease. Cell Mol Gastroenterol Hepatol 4:33–46.
2. Peterson LW, Artis D (2014) Intestinal epithelial cells: Regulators of barrier function and immune homeostasis. Nat Rev Immunol 14:141–153.
3. Sonnenberg GF, Fouser LA, Artis D (2011) Border patrol: Regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat Immunol 12: 383–390.
4. Turner JR (2009) Intestinal mucosal barrier function in health and disease. Nat Rev Immunol 9:799–809.
5. Sonnenberg GF, Fouser LA, Artis D (2010) Functional biology of the IL-22-IL-22R pathway in regulating immunity and inflammation at barrier surfaces. Adv Immunol 107:1–29.
6. Dudakov JA, Hanash AM, van den Brink MR (2015) Interleukin-22: Immunobiology and pathology. Annu Rev Immunol 33:747–785.
7. Sugimoto K, et al. (2008) IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest 118:534–544.
8. Zenewicz LA, et al. (2008) Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity 29:947–957.
9. Zheng Y, et al. (2008) Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat Med 14:282–289.
10. Zindl CL, et al. (2013) IL-22-producing neutrophils contribute to antimicrobial defense and restitution of colonic epithelial integrity during colitis. Proc Natl Acad Sci USA 110:12768–12773.
11. Eidenschenk C, Rutz S, Liesenfeld O, Ouyang W (2014) Role of IL-22 in microbial host defense. Curr Top Microbiol Immunol 380:213–236.
12. Rutz S, Wang X, Ouyang W (2014) The IL-20 subfamily of cytokines–From host de-fence to tissue homeostasis. Nat Rev Immunol 14:783–795.
13. Kinnebrew MA, et al. (2012) Interleukin 23 production by intestinal CD103(+)CD11b(+) dendritic cells in response to bacterial flagellin enhances mucosal innate immune defense. Immunity 36:276–287.
14. Shih VF, et al. (2014) Homeostatic IL-23 receptor signaling limits Th17 response through IL-22-mediated containment of commensal microbiota. Proc Natl Acad Sci USA 111:13942–13947.
15. Garlanda C, Dinarello CA, Mantovani A (2013) The interleukin-1 family: Back to the future. Immunity 39:1003–1018.
16. Lopetuso LR, Chowdhry S, Pizarro TT (2013) Opposing functions of classic and novel IL-1 family members in gut health and disease. Front Immunol 4:181.
17. Bamias G, Corridoni D, Pizarro TT, Cominelli F (2012) New insights into the dichotomous role of innate cytokines in gut homeostasis and inflammation. Cytokine 59:451–459.
18. Bamias G, Cominelli F (2016) Cytokines and intestinal inflammation. Curr Opin Gastroenterol 32:437–442.
19. Gabay C, Towne JE (2015) Regulation and function of interleukin-36 cytokines in homeostasis and pathological conditions. J Leukoc Biol 97:645–652.
20. Walsh PT, Fallon PG (2016) The emergence of the IL-36 cytokine family as novel targets for inflammatory diseases. Ann N Y Acad Sci 1417:23–34.
21. Russell SE, et al. (2016) IL-36α expression is elevated in ulcerative colitis and promotes colonic inflammation. Mucosal Immunol 9:1193–1204.
22. Medina-Contreras O, et al. (2016) Cutting edge: IL-36 receptor promotes resolution of intestinal damage. J Immunol 196:34–38.
23. Scheibe K, et al. (2016) IL-36R signalling activates intestinal epithelial cells and fibroblasts and promotes mucosal healing in vivo. Gut 66:823–838.
24. Nishida A, et al. (2016) Increased expression of interleukin-36, a member of the interleukin-1 cytokine family, in inflammatory bowel disease. Inflamm Bowel Dis 22: 303–314.
25. Boutet MA, et al. (2016) Distinct expression of interleukin (IL)-36α, β and γ, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn’s disease. Clin Exp Immunol 184:159–173.
26. Friedrich M, Tillack C, Wollenberg A, Schauber J, Brand S (2014) IL-36γ sustains a proinflammatory self-amplifying loop with IL-17C in anti-TNF-induced psoriasiform skin lesions of patients with Crohn’s disease. Inflamm Bowel Dis 20:1891–1901.
27. Takahashi K, et al. (2015) Interleukin (IL)-1β is a strong inducer of IL-36γ expression in human colonic myofibroblasts. PLoS One 10:e0138423.
28. Kanda T, et al. (2015) Interleukin(IL)-36α and IL-36γ induce proinflammatory mediators from human colonic subepithelial myofibroblasts. Front Med (Lausanne) 2:69.
29. Jiang Z, et al. (2017) IL-36gamma induced by the TLR3-SLUG-VDR axis promotes wound healing via REG3A. J Invest Dermatol 137:2620–2629.
30. Satpathy AT, et al. (2013) Notch2-dependent classical dendritic cells orchestrate intestinal immunity to attaching-and-effacing bacterial pathogens. Nat Immunol 14: 937–948.
31. Denning TL, et al. (2011) Functional specializations of intestinal dendritic cell and macrophage subsets that control Th17 and regulatory T cell responses are dependent on the T cell/APC ratio, source of mouse strain, and regional localization. J Immunol 187:733–747.
32. MacDonald KP, et al. (2010) An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammation. Blood 116:3955–3963.
33. Carmody RJ, Ruan Q, Liou HC, Chen YH (2007) Essential roles of c-Rel in TLR-induced IL-23 p19 gene expression in dendritic cells. J Immunol 178:186–191.
34. Luissint AC, Parkos CA, Nusrat A (2016) Inflammation and the intestinal barrier: Leukocyte-epithelial cell interactions, cell junction remodeling, and mucosal repair. Gastroenterology 151:616–632.
35. Round JL, Mazmanian SK (2009) The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol 9:313–323.
36. Zhou L, Sonnenberg GF (2018) Essential immunologic orchestrators of intestinal homeostasis. Sci Immunol 3:eaao1605.
37. Hooper LV, Littman DR, Macpherson AJ (2012) Interactions between the microbiota and the immune system. Science 336:1268–1273.
38. Aden K, et al. (2016) Epithelial IL-23R signaling licenses protective IL-22 responses in intestinal inflammation. Cell Rep 16:2208–2218.
39. Zenewicz LA, et al. (2013) IL-22 deficiency alters colonic microbiota to be transmissible and colitogenic. J Immunol 190:5306–5312.
40. Palomo J, Dietrich D, Martin P, Palmer G, Gabay C (2015) The interleukin (IL)-1 cytokine family–Balance between agonists and antagonists in inflammatory diseases. Cytokine 76:25–37.
41. Li N, et al. (2014) Alarmin function of cathelicidin antimicrobial peptide LL37 through IL-36γ induction in human epidermal keratinocytes. J Immunol 193:5140–5148.
42. Schlitzer A, et al. (2013) IRF4 transcription factor-dependent CD11b+ dendritic cells in human and mouse control mucosal IL-17 cytokine responses. Immunity 38:970–983.
43. Buonocore S, et al. (2010) Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology. Nature 464:1371–1375.
44. Morrison PJ, Ballantyne SJ, Kullberg MC (2011) Interleukin-23 and T helper 17-type responses in intestinal inflammation: From cytokines to T-cell plasticity. Immunology 133:397–408.
45. Awasthi A, et al. (2009) Cutting edge: IL-23 receptor gfp reporter mice reveal distinct populations of IL-17-producing cells. J Immunol 182:5904–5908.
46. Zenewicz LA, Flavell RA (2011) Recent advances in IL-22 biology. Int Immunol 23: 159–163.
47. Vivier E, Spits H, Cupedo T (2009) Interleukin-22-producing innate immune cells: New players in mucosal immunity and tissue repair? Nat Rev Immunol 9:229–234.
48. Colonna M (2009) Interleukin-22-producing natural killer cells and lymphoid tissue inducer-like cells in mucosal immunity. Immunity 31:15–23.
49. Chen F, et al. (2016) mTOR mediates IL-23 induction of neutrophil IL-17 and IL-22 production. J Immunol 196:4390–4399.
50. Parks OB, Pociask DA, Hodzic Z, Kolls JK, Good M (2016) Interleukin-22 signaling in the regulation of intestinal health and disease. Front Cell Dev Biol 3:85.
51. Mizoguchi A (2012) Healing of intestinal inflammation by IL-22. Inflamm Bowel Dis 18:1777–1784.
52. Becker C, et al. (2006) Cutting edge: IL-23 cross-regulates IL-12 production in T cell-dependent experimental colitis. J Immunol 177:2760–2764.
53. Mahil SK, et al. (2017) An analysis of IL-36 signature genes and individuals with IL1RL2 knockout mutations validates IL-36 as a psoriasis therapeutic target. Sci Transl Med 9: eaan2514, and erratum (2017) 9:eaar6600.
54. Harusato A, et al. (2017) IL-36γ signaling controls the induced regulatory T cell-Th9 cell balance via NFκB activation and STAT transcription factors. Mucosal Immunol 10:1455–1467.
55. Dietrich D, Gabay C (2014) Inflammation: IL-36 has proinflammatory effects in skin but not in joints. Nat Rev Rheumatol 10:639–640.
56. Gresnigt MS, van de Veerdonk FL (2013) Biology of IL-36 cytokines and their role in disease. Semin Immunol 25:458–465.
57. Deepak P, Sandborn WJ (2017) Ustekinumab and anti-interleukin-23 agents in Crohn’s disease. Gastroenterol Clin North Am 46:603–626.
58. Bamias G, Dinarello CA, Rivera-Nieves J (2015) Innate cytokines dictate the fate of acute intestinal inflammation. Gastroenterology 148:248–250.
59. Bersudsky M, et al. (2014) Non-redundant properties of IL-1α and IL-1β during acute colon inflammation in mice. Gut 63:598–609.
60. Elinav E, et al. (2011) NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 145:745–757.
61. Seregin SS, et al. (2017) NLRP6 function in inflammatory monocytes reduces susceptibility to chemically induced intestinal injury. Mucosal Immunol 10:434–445.
62. Monticelli LA, et al. (2015) IL-33 promotes an innate immune pathway of intestinal tissue protection dependent on amphiregulin-EGFR interactions. Proc Natl Acad Sci USA 112:10762–10767.
63. Dinarello CA, et al. (2016) Suppression of innate inflammation and immunity by interleukin-37. Eur J Immunol 46:1067–1081.
64. McNamee EN, et al. (2011) Interleukin 37 expression protects mice from colitis. Proc Natl Acad Sci USA 108:16711–16716.